US FDA expands use of Bristol Myers' cancer therapy

Breyanzi was initially approved in the United States in June 2022 to treat a type of blood cancer known as large B-cell lymphoma in adult patients whose disease has returned or stopped responding to treatment.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/nsPX1Cz
via